Inclusion criteria:
All women and men between the ages of 12 and 80 who have laboratory complications of Liver damage caused by Drug poisoning in the form of an increase in Liver enzymes AST, ALT more than 5 times the upper limit of normal, regardless of the presence of clinical symptoms, will be included in the study.
All women and men between the ages of 12 and 80 who have laboratory complications of Liver damage caused by drug poisoning in the form of an increase in AST, ALT, and ALKP to twice the upper limit of normal along with total Bilirubin above 2 mg/dl will be included in the study.
All women and men between the ages of 12 and 80 who have laboratory complications of Liver damage caused by drug poisoning in the form of an increase in AST, ALT to three times the upper limit of normal despite clinical symptoms (such as loss of appetite, fatigue, weakness and lethargy, nausea and vomiting, abdominal pain preferably epigastric and RUQ, itching, yellow skin or sclera, colorless stool or dark urine) will be included in the study.
Since Liver damage caused by drug poisoning may not necessarily have significant and clear clinical symptoms, the preferred entry criterion will be the elevation of Liver enzymes, which will determine the importance of clinical symptoms in decision making.
Exclusion criteria:
Patients with a history of underlying diseases of the Liver and Bile ducts (such as Alcoholic hepatitis, Autoimmune hepatitis, Non-alcoholic fatty liver disease (NAFLD), Viral hepatitis including Hepatitis B virus or Hepatitis C virus).